Hall J C, Christiansen K J, England P, Low A I, McRae P J, Mander J, Taylor T A, Hall J L
University Department of Surgery, Royal Perth Hospital, Perth, Australia.
Urology. 1996 Jun;47(6):852-6. doi: 10.1016/S0090-4295(96)00066-0.
To evaluate the prevention of urinary tract infections (UTIs) after transurethral resection of the prostate (TURP) in a prospective randomized study using a quinolone antibiotic (fleroxacin) to compare the efficacy of: (1) a single oral dose, (2) a single intravenous (IV) dose, and (3) an extended regimen consisting of an initial IV dose followed by oral therapy until removal of the urinary catheter, but for less than 6 days.
We excluded from study patients who received antimicrobial agents within 48 hours of surgery. Single-dose prophylaxis consisted of 400 mg of fleroxacin given either orally or intravenously. The extended regimen consisted of an initial 400 mg IV dose followed by 400 mg oral each day (patients older than 75 years, or with a creatinine clearance less than 40 mL/min, received 200 mg/day). UTI was defined as clinical evidence of infection plus the presence of more than 10 white blood cells (WBC)/mm3 in any urine specimen plus the presence of more than 10(4) cfu/mL in midstream urine specimens or more than 10(2) cfu/mL in catheter specimens.
Prior to TURP, 30% (25/84) of the patients had a urethral catheter in situ and 12% (3/25) of these patients had bacteriuria. Only 1 patient developed a UTI and that was 22 days after a TURP (intergroup comparisons, Fisher's exact test greater than 0.05). There were no instances of urosepsis.
A single oral dose of a fluoroquinolone agent provided optimum prophylaxis for patients undergoing TURP.
在一项前瞻性随机研究中,使用喹诺酮类抗生素(氟罗沙星)评估经尿道前列腺电切术(TURP)后预防尿路感染(UTI)的效果,以比较以下三种方案的疗效:(1)单次口服剂量;(2)单次静脉注射剂量;(3)一种延长疗程方案,即初始静脉注射剂量,随后口服治疗直至拔除导尿管,但疗程少于6天。
我们将在手术48小时内接受抗菌药物治疗的患者排除在研究之外。单剂量预防方案为口服或静脉注射400mg氟罗沙星。延长疗程方案为初始静脉注射400mg,随后每天口服400mg(75岁以上或肌酐清除率低于40mL/min的患者,每天服用200mg)。UTI定义为感染的临床证据,加上任何尿液标本中白细胞(WBC)超过10/mm³,以及中段尿标本中菌落形成单位(cfu)超过10⁴/mL或导尿管标本中cfu超过10²/mL。
在TURP之前,30%(25/84)的患者留置了尿道导尿管,其中12%(3/25)的患者有菌尿。只有1例患者发生了UTI,且是在TURP后22天(组间比较,Fisher精确检验大于0.05)。没有发生尿脓毒症的病例。
对于接受TURP的患者,单次口服氟喹诺酮类药物可提供最佳预防效果。